Catalog No.
RHB94404
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Alpaca
Isotype
VHH-8His-Cys-tag
Clonality
Monoclonal
Target
TNF, Tumor necrosis factor ligand superfamily member 2, N-terminal fragment, ICD2, NTF, TNF-a, TNF-alpha, Tumor necrosis factor, TNFSF2, TNFA, Cachectin, ICD1
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Purified by Nickel column.
Accession
P01375
Applications
ELISA, FCM, IF, SPR, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
SAA1201
Combined TNF-α and OX40L targeting as a new treatment option for hidradenitis suppurativa., PMID:40502542
Effects of immunotherapy on isolated optic neuritis associated with ozoralizumab, a novel anti-tumor necrosis factor α NANOBODY® compound: A case report., PMID:40486722
Development of potent humanized TNFα inhibitory nanobodies for therapeutic applications in TNFα-mediated diseases., PMID:40367237
Enhanced efficacy of dual chimeric antigen receptor-T cells targeting programmed death-ligand 1 and cancer-associated fibroblasts in colorectal cancer in vitro., PMID:40260068
New anti-TNF biologics in RA: What is new and what is old?, PMID:40180877
[Preparation of Trop2-Targeted CAR-T Cells Based on Nanobodies and Their Antitumor Effects Against Non-Small Cell Lung Cancer]., PMID:40109477
Therapeutic Advancements in Psoriasis and Psoriatic Arthritis., PMID:40004842
Inflammation-oriented montmorillonite adjuvant enhanced oral delivery of anti-TNF-α nanobody against inflammatory bowel disease., PMID:39226349
Preparation and Application of Clostridium perfringens Alpha Toxin Nanobodies., PMID:39195835
Engineering a Novel Probiotic Toolkit in Escherichia coli Nissle 1917 for Sensing and Mitigating Gut Inflammatory Diseases., PMID:39115381
Development of novel humanized CD19/BAFFR bicistronic chimeric antigen receptor T cells with potent antitumor activity against B-cell lineage neoplasms., PMID:38960449
Milk-derived extracellular vesicles functionalized with anti-tumour necrosis factor-α nanobody and anti-microbial peptide alleviate ulcerative colitis in mice., PMID:38840457
Dual engineered bacteria improve inflammatory bowel disease in mice., PMID:38739270
Novel bispecific nanobody mitigates experimental intestinal inflammation in mice by targeting TNF-α and IL-23p19 bioactivities., PMID:38533646
Biparatopic Nanobody-Based Immunosorbent for the Highly Selective Elimination of Tumor Necrosis Factor-α., PMID:38364210
Polyvalency: an emerging trend in the development of clinical antibodies., PMID:38029835
[Pharmacological profiles and clinical efficacy of ozoralizumab (Nanozora® 30 mg Syringes for S.C. Injection), the first Nanobody® compound in Japan]., PMID:37914330
Population Pharmacokinetics of Ozoralizumab in Patients with Rheumatoid Arthritis., PMID:37909264
Bispecific soluble cytokine receptor-nanobody fusions inhibit Interleukin (IL-)6 trans-signaling and IL-12/23 or tumor necrosis factor (TNF) signaling., PMID:37838173
Effect of the extended dosing interval of anti-TNF-α NANOBODY® compound ozoralizumab in patients with low disease activity rheumatoid arthritis., PMID:37804232
[Therapeutic antibodies in rheumatology]., PMID:37656186
Ozoralizumab: first Nanobody® therapeutic for rheumatoid arthritis., PMID:37431762
Structural, nonclinical, and clinical features of ozoralizumab: A novel tumour necrosis factor inhibitor., PMID:37185766
A bacteria-based system expressing anti-TNF-α nanobody for enhanced cancer immunotherapy., PMID:37072393
Efficacy and pharmacokinetics of ozoralizumab, an anti-TNFα NANOBODY® compound, in patients with rheumatoid arthritis: 52-week results from the OHZORA and NATSUZORA trials., PMID:37055803
Engineered Escherichia coli for the in situ secretion of therapeutic nanobodies in the gut., PMID:37003258
Nanobody targets TNF and IL-6 for additive efficacy., PMID:36894778
T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts., PMID:36875091
Additive efficacy of a bispecific anti-TNF/IL-6 nanobody compound in translational models of rheumatoid arthritis., PMID:36724239
Half-Life Extension and Biodistribution Modulation of Biotherapeutics via Red Blood Cell Hitch-Hiking with Novel Anti-Band 3 Single-Domain Antibodies., PMID:36613917
Ozoralizumab: First Approval., PMID:36509938
A novel anti-TNF-α drug ozoralizumab rapidly distributes to inflamed joint tissues in a mouse model of collagen induced arthritis., PMID:36302840
Efficacy and safety of anti-TNF multivalent NANOBODY® compound 'ozoralizumab' without methotrexate co-administration in patients with active rheumatoid arthritis: A 52-week result of phase III, randomised, open-label trial (NATSUZORA trial)., PMID:36201360
Efficacy and safety of the anti-TNF multivalent NANOBODY® compound ozoralizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: A 52-week result of a Phase II/III study (OHZORA trial)., PMID:36197757
SnoopLigase Enables Highly Efficient Generation of C-C-Linked Bispecific Nanobodies Targeting TNF-α and IL-17A., PMID:35938675
Phase II/III Results of a Trial of Anti-Tumor Necrosis Factor Multivalent NANOBODY Compound Ozoralizumab in Patients With Rheumatoid Arthritis., PMID:35729713
Identification of Anti-TNFα VNAR Single Domain Antibodies from Whitespotted Bambooshark (Chiloscyllium plagiosum)., PMID:35621957
TNF-α-Secreting Lung Tumor-Infiltrated Monocytes Play a Pivotal Role During Anti-PD-L1 Immunotherapy., PMID:35493461
The Therapeutic Effect of an Anti-TNF-α/HSA/IL-6R Triple-Specific Fusion Protein Under Experimental Septic Conditions., PMID:35059921
Selective IL-1 activity on CD8+ T cells empowers antitumor immunity and synergizes with neovasculature-targeted TNF for full tumor eradication., PMID:34772757
Early IFN-α signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19., PMID:34592166
A CTLA-4 blocking strategy based on Nanoboby in dendritic cell-stimulated cytokine-induced killer cells enhances their anti-tumor effects., PMID:34525966
Nanomedicine for acute respiratory distress syndrome: The latest application, targeting strategy, and rational design., PMID:33977080
Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy., PMID:33820820
Designing and constructing a phage display synthesized single domain antibodies library based on camel VHHs frame for screening and identifying humanized TNF-α-specific nanobody., PMID:33571835
Tumor necrosis factor α inhibition overcomes immunosuppressive M2b macrophage-induced bevacizumab resistance in triple-negative breast cancer., PMID:33214550
C-tag TNF: a reporter system to study TNF shedding., PMID:33082141
Preparation of RGD4C fused anti-TNFα nanobody and inhibitory activity on triple-negative breast cancer in vivo., PMID:32827545
Inflammation and joint destruction may be linked to the generation of cartilage metabolites of ADAMTS-5 through activation of toll-like receptors., PMID:31734268
Oral Anti-Tumour Necrosis Factor Domain Antibody V565 Provides High Intestinal Concentrations, and Reduces Markers of Inflammation in Ulcerative Colitis Patients., PMID:31575982
For research use only. Not for human or drug use.
